Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-10-31

Study Completion Date

2001-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Vulgaris Acne Propionibacterium Acnes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

acne acne vulgaris MBI 226 Propionibacterium acnes lesion counts lesions inflammatory non-inflammatory topical

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MBI 226 Acne Solutions

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females, ages 13 and up, exhibiting high levels of facial P. acnes
* Presence of inflammatory and non-inflammatory lesions

Exclusion Criteria

* Acne conglobata, acne fulminans, or secondary acne (chlorine, drug-induced acne, etc.)
* Active facial cysts

Minimum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jim Pankovich

Role: STUDY_DIRECTOR

BioWest Therapeutics Inc

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A99004

Identifier Type: -

Identifier Source: org_study_id